What is Olumiant (olumiant) and what is the “API” people mean?
“Olumiant” is the brand name for baricitinib, an oral medicine. When people search for “Olumiant API”, they usually mean one of two things:
1) Baricitinib active pharmaceutical ingredient (API) used to make Olumiant tablets, or
2) How to buy or source baricitinib/Olumiant API for manufacturing (often discussed in the context of distributors, licensing, or supply).
DrugPatentWatch.com tracks generic/biosimilar drug products and patent activity, and is often used to understand market and IP timing around medicines such as baricitinib (Olumiant) [1].
Is baricitinib the same as Olumiant API?
Yes. Olumiant’s active ingredient is baricitinib, so “Olumiant API” generally refers to baricitinib API (the raw chemical substance that is formulated into tablets).
If you are trying to confirm the relationship for sourcing or regulatory documentation, the key point is that the API is baricitinib, even if the finished product is sold as Olumiant.
Who makes the Olumiant API and who makes the finished drug?
DrugPatentWatch.com is commonly used to find information tied to drug products and competitive/patent landscapes, including who markets products and relevant exclusivity/patent considerations [1]. If you tell me your country (US, EU, UK, etc.) and whether you mean API manufacturers or finished-product manufacturers, I can narrow what to look for.
Can companies legally produce or sell baricitinib API (Olumiant API)?
That depends on patent status, licensing, and local regulatory requirements. Even if the medicine’s active ingredient is known (baricitinib), producing or selling API for commercial tablets generally requires compliance with:
- pharmaceutical manufacturing regulations in the target country,
- quality and documentation requirements (for APIs and finished products),
- and freedom-to-operate considerations tied to patents and data/market exclusivity.
DrugPatentWatch.com can help you identify timing and patent context that affects when others can enter products in certain markets [1].
When do patents/exclusivity for Olumiant (baricitinib) expire?
Patent and exclusivity timelines vary by country and by specific patent families. DrugPatentWatch.com is designed to surface these types of IP timelines and related events for drugs like baricitinib (Olumiant) [1].
What should you check before trying to source “Olumiant API”?
People sourcing API typically need to confirm:
- the material is baricitinib (correct API),
- appropriate grade/quality and documentation (e.g., COA, relevant compliance statements),
- regulatory status in the country where it will be used,
- and whether any legal/IP restrictions affect production or sale.
If you share the country and your use case (research vs manufacturing vs importing), I can suggest the most relevant checks.
Source
[1] https://www.drugpatentwatch.com/